Exai Bio

Exai Bio is a next-generation liquid biopsy company based in Palo Alto, California. The company employs 51 people and generates $50 million in annual revenue. Exai Bio specializes in developing RNA and artificial intelligence-based liquid biopsy platforms. These platforms provide clinical insights into cancer biology, enabling the earliest and most accurate diagnosis of cancer. Their technology aims to revolutionize cancer detection, diagnosis, treatment, and ultimately, cure. The company was founded using technology from the UCSF laboratory of Dr. Hani Goodarzi and is staffed by experienced professionals from leading institutions like UCSF, Stanford, MIT, Bluestar, CareDx, Evidation, Google, 23andMe, and Deep Genomics. Exai Bio's dedication to its mission is supported by prominent life sciences and tech investors such as Section 32, Casdin Capital, and Two Sigma Ventures. Exai Bio can be reached through their website at exai.bio.